Pharmacokinetics of Micafungin in Patients of Intensive Care Units

Status Completed

Clinical Trial Summary

Invasive fungal infections (IFIs) are a frequent cause of morbidity and mortality in high-risk patients, such as immunocompromised patients. Candida is currently the predominant fungal pathogen in these patient populations and is associated with significant morbidity and a high mortality.

Micafungin (MCF) is a semisynthetic compound belonging to the new class of antifungal agents, the echinocandin lipopeptides, that has potent in vitro and experimental in vivo activity against a variety of pathogenic Candida species and Aspergillus species. Its applied indications are so the treatment and/or the prophylaxis of Candida and Aspergillus infections. MCF is currently licensed for the treatment of candidiasis at doses of either 100 or 150 mg a day.

The efficacy of MCF is linked to the area under the concentration-time curve over 24 h in the steady state divided by the MIC (AUC0-24/ MIC ratio).

On one hand:

- It was demonstrated that 98% of invasive candidiasis patients with a MCF AUC/MIC ratio between 3 and 12 achieve microbiological clearance, as opposed to only 85% of those with an AUC/MIC ratio < 3. In the case of infections by Candida parapsilosis, which exhibits drug MICs that are 50- to100-fold higher, 100% of patients with an AUC/MIC ratio >285 achieve microbiological clearance, as opposed to 82% of those below that exposure level.(1)

On the other hand:

- It is well known that patients of intensive care units (ICU) are characterized by particular pharmacokinetic parameters with higher apparent volume of distribution (VC/F) and/or higher apparent systemic clearance (CL/F). In a population of healthy volunteers, it was observed that CL/F of MCF presents a high interpatient variability.(2)

- Whether most ICUs patients achieve optimal AUC/MIC ratio thresholds at standard doses has not been investigated so far. In particular, lower AUCs might be reached in patients having the highest VC/F values. Such patients would then be at risk of therapy failure and would benefit from individualized-dosing strategies.

In this context, the study of the pharmacokinetics of MCF in critically ill patients seems to be necessary.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02164890
Study type	Interventional
Source	University Hospital, Limoges
Contact
Status	Completed
Phase	Phase 4
Start date	June 2014
Completion date	December 2016

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05763251` - Comparison of Uncomplicated Candidemia Therapy Duration in Children	N/A
Recruiting	`NCT01438216` - Anidulafungin Pharmacokinetics in Intensive Care Unit Patients	N/A
Terminated	`NCT01213823` - Risk Of Severe Hepatic Injury In Patients With Invasive Candidiasis Treated With Echinocandins	Phase 4
Completed	`NCT02491151` - Variability of Fluconazole Concentration in Critically Ill Patients	N/A
Completed	`NCT01716988` - Pharmacokinetics of Micafungin in Critically Ill Patients	N/A
Completed	`NCT00607763` - Study of Mycamine® in Infants and Toddlers With Fungal Infections to Evaluate Safety and Blood Levels of the Drug	Phase 1
Completed	`NCT00608335` - Study of Mycamine® in Children With Fungal Infections to Evaluate Safety and Blood Levels of the Drug	Phase 1
Completed	`NCT00786903` - Candida Spp. in the Lower Respiratory Tract: Harmless Residents or Pathogen?	N/A
Completed	`NCT00670657` - CRITIC - Treatment of Candidemia and Invasive Candidiasis	Phase 4
Recruiting	`NCT04368559` - Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation	Phase 3
Not yet recruiting	`NCT05707832` - A Study of ABCD for Injection in Subjects With Invasive Candidiasis and Invasive Aspergillus	Phase 3
Recruiting	`NCT03538912` - Early Discontinuation of Empirical Antifungal Therapy and Biomarkers	N/A
Completed	`NCT02801682` - NOBICS - NOvel BIomarker In Invasive CandidiasiS/Candida Sepsis
Completed	`NCT02841501` - Genetic Susceptibility Factors for Candidemia.
Completed	`NCT01047267` - Pharmacokinetics of Anidulafungin on Intensive Care Unit (ICU)	N/A
Completed	`NCT00672841` - β-D-Glucan (BDG) Surveillance With Preemptive Anidulafungin vs. Standard Care for Invasive Candidiasis in Surgical Intensive Care Unit (SICU) Patients	N/A
Completed	`NCT02734862` - CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension	Phase 2
Completed	`NCT01773876` - Empirical Antifungal Treatment in ICUS	Phase 3
Completed	`NCT00689338` - Anidulafungin Candidemia/Invasive Candidiasis Intensive Care Study	Phase 3
Terminated	`NCT03906916` - Comparison of Two Diagnostic Tests in Patients With Suspected Invasive Candidiasis in Internal Medicine Wards and Who Are Currently Timely Treated With Micafungin	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Pharmacokinetics of Micafungin in Patients of Intensive Care Units — MI-K

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms